Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400

8 October 2026 · By · Wire by Fusion42

Published

8 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 10 October 2026 · Fusion42 review

Edgewise Therapeutics has started dosing patients in its Phase 2 EQUINOX-HFpEF trial to evaluate EDG-15400, a selective cardiac sarcomere modulator for treating heart failure with preserved ejection fraction (HFpEF). The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with symptomatic HFpEF.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a new opportunity to serve an underserved heart failure segment where current treatments fall short. This trial's focus on a novel mechanism could open a niche market if the drug proves effective.

◆ Coverage

1 source · 8 Oct 2026

◆ Related on Wire

◆ Topics

Biotechhfpefclinical-trialcardiovasculardrug-developmentpharmaceuticals